Apoptosis induction by doxazosin and other quinazoline α1-adrenoceptor antagonists: a new mechanism for cancer treatment?

ALLHAT Research Group (2000) Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 283:1967–1975

Anglin IE, Glassman DT, Kyprianou N (2002) Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis 5:88–95

Austin PF, Cook BL, Niederhoff RA, Manson SR, Coplen DE, Weintraub SJ (2004) Inhibition of mitogenic signaling and induction of apoptosis in human bladder smooth muscle cells treated with doxazosin. J Urol 172:1662–1665

Benning CM, Kyprianou N (2002) Quinazoline-derived α1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an α1-adrenoceptor-independent action. Cancer Res 62:597–603

Chon JK, Borkowski A, Partin AW, Isaacs JT, Jacobs SC, Kyprianou N (1999) Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol 161:2002–2008

Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH et al (1986) Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 314:1547–1552

Cuellar DC, Rhee J, Kyprianou N (2002) Alpha1-adrenoceptor antagonists radiosensitize prostate cancer cells via apoptosis induction. Anticancer Res 22:1673–1679

Duan WR, Garner DS, Williams SD, Funckes-Shippy CL, Spath IS, Blomme EA (2003) Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol 199:221–228

Eiras S, Fernandez P et al (2006) Doxazosin induces activation of GADD153 and cleavage of focal adhesion kinase in cardiomyocytes en route to apoptosis. Cardiovasc Res 71:118–128

Fernando MA, Heaney AP (2005) α1-Adrenergic receptor antagonists: novel therapy for pituitary adenomas. Mol Endocrinol 19:3085–3096

Frisch SM, Screaton RA (2001) Anoikis mechanisms. Curr Opin Cell Biol 13:555–562

Gan L, Zhu D, Yang L, Liu R, Yan F, Zhang J (2008) Involvement of transcription factor activator protein-2α in doxazosin-induced HeLa cell apoptosis. Acta Pharmacol Sin 29:465–472

Garrison JB, Kyprianou N (2006) Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. Cancer Res 66:464–472

Garrison JB, Shaw YJ, Chen CS, Kyprianou N (2007) Novel quinazoline-based compounds impair prostate tumorigenesis by targeting tumor vascularity. Cancer Res 67:11344–11352

Gavrieli Y, Sherman Y, Ben-Sasson SA (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493–501

Gonzalez-Juanatey JR, Iglesias MJ, Alcaide C, Piñeiro R, Lago F (2003) Doxazosin induces apoptosis in cardiomyocytes cultured in vitro by a mechanism that is independent of α1-adrenergic blockade. Circulation 107:127–131

Grasl-Kraupp B, Ruttkay-Nedecky B, Koudelka H, Bukowska K, Bursch W, Schulte-Hermann R (1995) In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: a cautionary note. Hepatology 21:1465–1468

Harris AM, Warner BW, Wilson JM, Becker A, Rowland RG, Conner W, Lane M, Kimbler K, Durbin EB, Baron AT, Kyprianou N (2007) Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study. J Urol 178:2176–2180

Hui H, Fernando MA, Heaney AP (2008) The α1-adrenergic receptor antagonist doxazosin inhibits EGFR and NF-кB signaling to induce breast cancer cell apoptosis. Eur J Cancer 44:160–166

Keledjian K, Garrison JB, Kyprianou N (2005) Doxazosin inhibits vascular endothelial cell adhesion, migration and invasion. J Cell Biochem 94:374–388

Kelly KJ, Sandoval RM, Dunn KW, Molitoris BA, Dagher PC (2003) A novel method to determine specificity and sensitivity of the TUNEL reaction in the quantitation of apoptosis. Am J Physiol Cell Physiol 284:C1309–C1318

Kiehn J, Thomas D, Karle CA, Schöls W, Kübler W (1999) Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol 359:212–219

Kirby RS (1995) Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men. Urology 46:182–186

Kockx MM, Muhring J, Knaapen MW, de Meyer GR (1998) RNA synthesis and splicing interferes with DNA in situ end labeling techniques used to detect apoptosis. Am J Pathol 152:885–888

Kyprianou N, Benning CM (2000) Suppression of human prostate cancer cell growth by alpha 1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res 60:4550–4555

Kyprianou N, Litvak JP, Barkowski A, Alexander R, Jacobs SC (1998) Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol 159:1810–1815

Lin SC, Chueh SC, Hsiao CJ, Li TK, Chen TH, Liao CH, Lyu PC, Guh JH (2007) Prazosin displays anticancer activity against human prostate cancers: targeting DNA and cell cycle. Neoplasia 9:830–839

McConnell JD et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387–2398

Michel MC, Kenny B, Schwinn DA (1995) Classification of alpha 1-adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol 352:1–10

Partin JV, Anglin IE, Kyprianou N (2003) Quinazoline-based alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signaling and I kappa B alpha induction. Br J Cancer 88:1615–1621

Rennebeck G, Martelli M, Kyprianou N (2005) Anoikis and survival connections in the reactive tumor microenvironment: significance in prostate cancer metastasis. Cancer Res 63:11230–11235

Rodriguez-Feo JA, Forbes J et al (2000) Doxazosin modifies Bcl-2 and Bax protein expression in the left ventricle of spontaneously hypertensive rats. J Hypertens 18:307–315

Roehrborn CG (2006) Three months' treatment with the α1-blocker alfuzosin does not affect total or transition zone volume of the prostate. Prostate Cancer Prostatic Dis 9:121–125

Shaw YJ, Yang YT, Garrison JB, Kyprianou N, Chen CS (2004) Pharmacological exploitation of the alpha1-adrenoreceptor antagonist doxazosin to develop a novel class of antitumor agents that block intracellular protein kinase B/Akt activation. J Med Chem 47:4453–4462

Siddiqui EJ, Shabbir M, Thompson CS, Mumtaz FH, Mikhailidis DP (2005) Growth inhibitory effect of doxazosin on prostate and bladder cancer cells. Is the serotonin receptor pathway involved? Anticancer Res 25:4281–4286

Smith GAM, Tsui HW, Newell EW, Jiang X, Zhu XP, Tsui FWL, Schlichter LC (2002) Functional up-regulation of HERG K+ channels in neoplastic hematopoietic cells. J Biol Chem 277:18528–18534

Tahmatzopoulos A, Kyprianou N (2004) Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality? Prostate 59:91–100

Tahmatzopoulos A, Rowland RG, Kyprianou N (2004) The role of alpha-blockers in the management of prostate cancer. Expert Opin Pharmacother 5:1279–1285

Tahmatzopoulos A, Lagrange CA, Zeng L, Mitchell BL, Conner WT, Kyprianou N (2005) Effect of terazosin on tissue vascularity and apoptosis in transitional cell carcinoma of bladder. Urology 65:1019–1023

Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA (2004) Inhibition of human ether-a-go-go-related gene potassium channels by α1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol 369:462–472

Thomas D, Bloehs R, Koschny R, Ficker E, Sykora J, Kiehn J, Schlömer K, Gierten J, Kathöfer S, Zitron E, Scholz EP, Kiesecker C, Katus HA, Karle CA (2008) Doxazosin induces apoptosis of cells expressing hERG K+ channels. Eur J Pharmacol 579:98–103

Yang G, Timme TL, Park SH, Wu X, Wyllie MG, Thompson TC (1997) Transforming growth factor β1 transduced mouse prostate reconstitutions: II. Induction of apoptosis by doxazosin. Prostate 33:157–164

Yang Y-F, Wu C-C, Chen W-P, Su M-J (2009) Transforming growth factor-beta type I receptor/ALK5 contributes to doxazosin-induced apoptosis in H9C2 cells. Naunyn Schmiedebergs Arch Pharmacol (in press)

Yasuda M, Umemura S, Osamura RY, Kenjo T, Tsutsuni Y (1995) Apoptotic cells in the human endometrium and placental villi: pitfalls in applying the TUNEL method. Arch Histol Cytol 58:185–190